Personalis Secures Medicare Coverage, Boosts Cash with $130M ATM Raise, and Reports 400% Clinical Volume Growth

summarizeSummary

Personalis, Inc. filed its annual 10-K, reporting a significant capital raise through its ATM facility and key Medicare coverage approvals for its NeXT Personal Dx tests, alongside a substantial increase in clinical test volume, despite a revenue decline from a major customer.

check_boxKey Events

• Strong Capital Position

  The company raised $109.0 million in net proceeds from its At-The-Market (ATM) sales program in 2025, with an additional $21.0 million raised in January 2026. This significantly increased cash, cash equivalents, and short-term investments to $240.0 million by December 31, 2025.

• Key Medicare Coverage Secured

  Personalis received Medicare coverage for its NeXT Personal Dx test for post-treatment surveillance of Stage II and III breast cancer in November 2025, and for Stage I to III non-small cell lung cancer in February 2026. These are expected to be key catalysts for clinical revenue growth.

• Clinical Test Volume Surges

  Clinical test volume increased by nearly 400% in 2025, reaching 16,233 tests, compared to 3,285 tests in 2024. Clinical test revenue more than doubled to $2.0 million in 2025 from $0.8 million in 2024.

• Natera Partnership Wind-Down

  Revenue from Natera, previously a significant customer, declined from 30% of total revenue in 2024 to 8% in 2025. The company stated it no longer has a material commercial relationship with Natera and does not expect to have one going forward.

auto_awesomeAnalysis

This 10-K provides a comprehensive update on Personalis' strategic pivot and financial health. The successful capital raises through the ATM facility significantly strengthen the company's liquidity, providing a longer runway for operations and growth initiatives. The achievement of Medicare coverage for its NeXT Personal Dx tests in two major cancer indications is a critical commercial milestone, expected to drive future clinical revenue and market share growth. This is further supported by the substantial increase in clinical test volume. While the winding down of the material relationship with Natera presents a revenue headwind, the company's focus on clinical diagnostics and population sequencing (VA MVP) appears to be generating new growth. The favorable regulatory outcome regarding LDTs also reduces potential future compliance burdens. Investors should monitor the continued ramp-up of clinical revenue and the company's ability to diversify its customer base effectively.